{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:09Z","timestamp":1787851329147,"version":"build-2784847793"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The interaction between HER2 and ER\u03b1 signaling pathways contributes to resistance to anti-estrogen and HER2-targeted therapies, presenting substantial treatment challenges in ER-positive (ER+) HER2-positive (HER2+) mammary carcinoma (MC). Trefoil Factor-3 (TFF3) has been reported to mediate resistance to both anti-estrogen and anti-HER2 targeted therapies in ER+ and ER+HER2+\u2009MC, respectively. Herein, the function and mechanism of TFF3 in ER+HER2+\u2009MC were delineated; and novel combinatorial therapeutic strategies were identified. Elevated expression of TFF3 promoted the oncogenicity of ER+HER2+\u2009MC cells, including enhanced cell proliferation, survival, anchorage-independent growth, 3D growth, cancer stem cell-like (CSC-like) phenotype, migration, invasion, and xenograft growth. Targeting TFF3 with an interfering RNA plasmid or a small-molecule inhibitor (AMPC) inhibited these oncogenic characteristics, highlighting the therapeutic potential of targeting TFF3 in ER+HER2+\u2009MC. Furthermore, a high-throughput combinatorial anti-cancer compound library screening revealed that AMPC preferentially synergized with receptor tyrosine kinase c-MET inhibitors (c-METis) to reduce cell survival and the CSC-like phenotype. The combination of AMPC and c-METis also synergistically suppressed the in vivo growth of ER+HER2+\u2009MC cell-derived xenografts and abrogated lung metastasis. Mechanistically, TFF3 was observed to activate c-MET signaling through a positive-feedback loop to enhance the CSC-like phenotype of ER+HER2+\u2009MC. Therefore, proof of concept is provided herein that antagonizing of TFF3 is a promising therapeutic strategy in combination with c-MET inhibition for the treatment of ER+HER2+\u2009MC.<\/jats:p>","DOI":"10.1038\/s41419-025-07387-5","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T23:23:56Z","timestamp":1738884236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-4594","authenticated-orcid":false,"given":"Chuyu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shiou","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-468X","authenticated-orcid":false,"given":"Basappa","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-1144","authenticated-orcid":false,"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-0694","authenticated-orcid":false,"given":"Vijay","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8445-184X","authenticated-orcid":false,"given":"Peter E.","family":"Lobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"7387_CR1","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.ajpath.2017.04.022","volume":"187","author":"HG Russnes","year":"2017","unstructured":"Russnes HG, Lingj\u00e6rde OC, B\u00f8rresen-Dale A-L, Caldas C. Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. Am J Pathol. 2017;187:2152\u201362.","journal-title":"Am J Pathol"},{"key":"7387_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/sj.bjc.6605799","volume":"103","author":"CA Purdie","year":"2010","unstructured":"Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer. 2010;103:475\u201381.","journal-title":"Br J Cancer"},{"key":"7387_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00533-2","volume":"9","author":"M Pegram","year":"2023","unstructured":"Pegram M, Jackisch C, Johnston SRD. Estrogen\/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive\/HER2-positive breast cancer. NPJ Breast Cancer. 2023;9:45.","journal-title":"NPJ Breast Cancer"},{"key":"7387_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2217\/fon-2020-0504","volume":"17","author":"C Kay","year":"2021","unstructured":"Kay C, Mart\u00ednez-P\u00e9rez C, Meehan J, Gray M, Webber V, Dixon JM, et al. Current trends in the treatment of HR+\/HER2+ breast cancer. Future Oncol. 2021;17:1665\u201381.","journal-title":"Future Oncol"},{"key":"7387_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet"},{"key":"7387_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975463","volume":"12","author":"R Ran","year":"2022","unstructured":"Ran R, Ma Y, Wang H, Yang J, Yang J. Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+\/HER2+) metastatic breast cancer: a review. Front Oncol. 2022;12:975463.","journal-title":"Front Oncol"},{"key":"7387_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41419-022-04504-6","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lin Z, Lin Q, Bei W, Guo J. Pathological and therapeutic roles of bioactive peptide trefoil factor 3 in diverse diseases: recent progress and perspective. Cell Death Dis. 2022;13:62.","journal-title":"Cell Death Dis"},{"key":"7387_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/path.1147","volume":"197","author":"WK Leung","year":"2002","unstructured":"Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002;197:582\u20138.","journal-title":"J Pathol"},{"key":"7387_CR9","doi-asserted-by":"crossref","unstructured":"Chen RM, Chiou YS, Chong QY, Poh HM, Tan TZ, Zhang MY, et al. Pharmacological inhibition of TFF3 enhances sensitivity of CMS4 colorectal carcinoma to 5-fluorouracil through inhibition of p44\/42 MAPK. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20246215"},{"key":"7387_CR10","doi-asserted-by":"publisher","first-page":"39323","DOI":"10.18632\/oncotarget.16950","volume":"8","author":"ML You","year":"2017","unstructured":"You ML, Chen YJ, Chong QY, Wu MM, Pandey V, Chen RM, et al. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget. 2017;8:39323\u201344.","journal-title":"Oncotarget"},{"key":"7387_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2130229","volume":"2021","author":"Y Xin","year":"2021","unstructured":"Xin Y, Shang X, Sun X, Liu Y, Xu G, Xue G. Trefoil factor 3 inhibits thyroid cancer cell progression related to IL-6\/JAK\/STAT3 signaling pathway. Evid Based Complement Altern Med. 2021;2021:2130229.","journal-title":"Evid Based Complement Altern Med"},{"key":"7387_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0173-8","volume":"8","author":"M Zhang","year":"2019","unstructured":"Zhang M, Wang B, Chong Q-Y, Pandey V, Guo Z, Chen R-M, et al. A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1\/2 inhibition in lung adenocarcinoma. Oncogenesis. 2019;8:65.","journal-title":"Oncogenesis"},{"key":"7387_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41419-022-04700-4","volume":"13","author":"F Cheng","year":"2022","unstructured":"Cheng F, Wang X, Chiou YS, He C, Guo H, Tan YQ, et al. Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression. Cell Death Dis. 2022;13:265.","journal-title":"Cell Death Dis"},{"key":"7387_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2015.02.051","volume":"361","author":"O Perera","year":"2015","unstructured":"Perera O, Evans A, Pertziger M, MacDonald C, Chen H, Liu DX, et al. Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation. Cancer Lett. 2015;361:104\u201311.","journal-title":"Cancer Lett"},{"key":"7387_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-016-0379-1","volume":"17","author":"Z Yuan","year":"2017","unstructured":"Yuan Z, Chen D, Chen X, Yang H, Wei Y. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int. 2017;17:7.","journal-title":"Cancer Cell Int"},{"key":"7387_CR16","doi-asserted-by":"publisher","first-page":"77268","DOI":"10.18632\/oncotarget.20461","volume":"8","author":"V Pandey","year":"2017","unstructured":"Pandey V, Zhang M, Chong QY, You M, Raquib AR, Pandey AK, et al. Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells. Oncotarget. 2017;8:77268\u201391.","journal-title":"Oncotarget"},{"key":"7387_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1593\/neo.10916","volume":"12","author":"N Kannan","year":"2010","unstructured":"Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, et al. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010;12:1041\u201353.","journal-title":"Neoplasia"},{"key":"7387_CR18","doi-asserted-by":"publisher","first-page":"74188","DOI":"10.18632\/oncotarget.18431","volume":"8","author":"QY Chong","year":"2017","unstructured":"Chong QY, You ML, Pandey V, Banerjee A, Chen YJ, Poh HM, et al. Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+\/ER+ mammary carcinoma. Oncotarget. 2017;8:74188\u2013208.","journal-title":"Oncotarget"},{"key":"7387_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13058-014-0429-3","volume":"16","author":"V Pandey","year":"2014","unstructured":"Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T, et al. Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 2014;16:429.","journal-title":"Breast Cancer Res"},{"key":"7387_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216443","volume":"579","author":"H Guo","year":"2023","unstructured":"Guo H, Tan YQ, Huang X, Zhang S, Basappa B, Zhu T, et al. Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma. Cancer Lett. 2023;579:216443.","journal-title":"Cancer Lett"},{"key":"7387_CR21","doi-asserted-by":"crossref","unstructured":"Poh HM, Chiou YS, Chong QY, Chen RM, Rangappa KS, Ma L, et al. Inhibition of TFF3 enhances sensitivity-and overcomes acquired resistance-to doxorubicin in estrogen receptor-positive mammary carcinoma. Cancers. 2019;11.","DOI":"10.3390\/cancers11101528"},{"key":"7387_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1167\/iovs.15-18129","volume":"57","author":"J Dieckow","year":"2016","unstructured":"Dieckow J, Brandt W, Hattermann K, Schob S, Schulze U, Mentlein R, et al. CXCR4 and CXCR7 Mediate TFF3-Induced Cell Migration Independently From the ERK1\/2 Signaling Pathway. Investig Ophthalmol Vis Sci. 2016;57:56\u201365.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"7387_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-021-00677-2","volume":"6","author":"HY Cui","year":"2021","unstructured":"Cui HY, Wang SJ, Song F, Cheng X, Nan G, Zhao Y, et al. CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. Signal Transduct Target Ther. 2021;6:268.","journal-title":"Signal Transduct Target Ther"},{"key":"7387_CR24","doi-asserted-by":"publisher","first-page":"e64441","DOI":"10.1371\/journal.pone.0064441","volume":"8","author":"J Madsen","year":"2013","unstructured":"Madsen J, Sorensen GL, Nielsen O, Tornoe I, Thim L, Fenger C, et al. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS One. 2013;8:e64441.","journal-title":"PLoS One"},{"key":"7387_CR25","first-page":"332","volume":"117","author":"GJ Barrera","year":"2016","unstructured":"Barrera GJ, Tortolero GS. Trefoil factor 3 (TFF3) from human breast milk activates PAR-2 receptors, of the intestinal epithelial cells HT-29, regulating cytokines and defensins. Bratisl Lek Listy. 2016;117:332\u20139.","journal-title":"Bratisl Lek Listy"},{"key":"7387_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12315-1","volume":"10","author":"NM Belle","year":"2019","unstructured":"Belle NM, Ji Y, Herbine K, Wei Y, Park J, Zullo K, et al. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Commun. 2019;10:4408.","journal-title":"Nat Commun"},{"key":"7387_CR27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/eji.202048768","volume":"51","author":"J Liu","year":"2021","unstructured":"Liu J, Yang Q, Chen Z, Lv S, Tang J, Xing Z, et al. TFF3 mediates the NF-kappaB\/COX2 pathway to regulate PMN-MDSCs activation and protect against necrotizing enterocolitis. Eur J Immunol. 2021;51:1110\u201325.","journal-title":"Eur J Immunol"},{"key":"7387_CR28","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.3892\/ijmm.2017.3120","volume":"40","author":"J Guo","year":"2017","unstructured":"Guo J, Xu L, Teng X, Sun M. MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase\/Akt signalling pathway. Int J Mol Med. 2017;40:1435\u201343.","journal-title":"Int J Mol Med"},{"key":"7387_CR29","first-page":"1","volume":"50","author":"J Liu","year":"2018","unstructured":"Liu J, Kim SY, Shin S, Jung S-H, Yim S-H, Lee JY, et al. Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis. Exp Mol Med. 2018;50:1\u201311.","journal-title":"Exp Mol Med"},{"key":"7387_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1021\/acsptsci.2c00044","volume":"5","author":"V Pandey","year":"2022","unstructured":"Pandey V, Zhang X, Poh H-M, Wang B, Dukanya D, Ma L, et al. Monomerization of homodimeric trefoil factor 3 (TFF3) by an aminonitrile compound inhibits TFF3-dependent cancer cell survival. ACS Pharmacol Transl Sci. 2022;5:761\u201373.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"7387_CR31","doi-asserted-by":"publisher","first-page":"5625","DOI":"10.1158\/0008-5472.CAN-12-1305","volume":"72","author":"J Cui","year":"2012","unstructured":"Cui J, Germer K, Wu T, Wang J, Luo J, Wang SC, et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res. 2012;72:5625\u201334.","journal-title":"Cancer Res"},{"key":"7387_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/(SICI)1096-9896(199708)182:4<404::AID-PATH875>3.0.CO;2-0","volume":"182","author":"FE May","year":"1997","unstructured":"May FE, Westley BR. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol. 1997;182:404\u201313.","journal-title":"J Pathol"},{"key":"7387_CR33","first-page":"5979","volume":"61","author":"S Gruvberger","year":"2001","unstructured":"Gruvberger S, Ringn\u00e9r M, Chen Y, Panavally S, Saal LH, Borg \u00c5, et al. Estrogen receptor status breast cancer is associated remarkably distinct gene expression patterns. Cancer Res 2001;61:5979\u201384.","journal-title":"Cancer Res"},{"key":"7387_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1530\/ERC-15-0129","volume":"22","author":"FE May","year":"2015","unstructured":"May FE, Westley BR. TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr-Relat Cancer. 2015;22:465\u201379.","journal-title":"Endocr-Relat Cancer"},{"key":"7387_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-015-3644-4","volume":"154","author":"KG Thomsen","year":"2015","unstructured":"Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, et al. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Res Treat. 2015;154:483\u201394.","journal-title":"Breast Cancer Res Treat"},{"key":"7387_CR36","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","volume":"276","author":"RA Campbell","year":"2001","unstructured":"Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;276:9817\u201324.","journal-title":"J Biol Chem"},{"key":"7387_CR37","doi-asserted-by":"crossref","unstructured":"Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, et al. Expression of c-MET in estrogen receptor positive and HER2 negative resected breast cancer correlated with a poor prognosis. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11236987"},{"key":"7387_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","volume":"17","author":"CM Ho-Yen","year":"2015","unstructured":"Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52.","journal-title":"Breast Cancer Res"},{"key":"7387_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155379","volume":"128","author":"CD Mohan","year":"2024","unstructured":"Mohan CD, Shanmugam MK, Gowda SGS, Chinnathambi A, Rangappa KS, Sethi G. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy. Phytomedicine. 2024;128:155379.","journal-title":"Phytomedicine"},{"key":"7387_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/aps.2010.106","volume":"31","author":"MH Wang","year":"2010","unstructured":"Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET\/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharm Sin. 2010;31:1181\u20138.","journal-title":"Acta Pharm Sin"},{"key":"7387_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201.","journal-title":"Signal Transduct Target Ther"},{"key":"7387_CR42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41419-022-04982-8","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Huang P, Wang L, Chen S, Basappa B, Zhu T, et al. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma. Cell Death Dis. 2022;13:558.","journal-title":"Cell Death Dis"},{"key":"7387_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41419-024-06551-7","volume":"15","author":"YQ Tan","year":"2024","unstructured":"Tan YQ, Sun B, Zhang X, Zhang S, Guo H, Basappa B, et al. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS(G12D)-mutant pancreatic ductal adenocarcinoma. Cell Death Dis. 2024;15:173.","journal-title":"Cell Death Dis"},{"key":"7387_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00489-3","volume":"8","author":"YQ Tan","year":"2024","unstructured":"Tan YQ, Chiou YS, Guo H, Zhang S, Huang X, Dukanya D, et al. Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple-negative breast cancer. NPJ Precis Oncol. 2024;8:8.","journal-title":"NPJ Precis Oncol"},{"key":"7387_CR45","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1210\/en.2009-0979","volume":"151","author":"V Pandey","year":"2010","unstructured":"Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, et al. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology. 2010;151:909\u201320.","journal-title":"Endocrinology"},{"key":"7387_CR46","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41374-018-0057-0","volume":"98","author":"DK Meyerholz","year":"2018","unstructured":"Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Investig. 2018;98:844\u201355.","journal-title":"Lab Investig"},{"key":"7387_CR47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"7387_CR48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11523-017-0508-3","volume":"12","author":"JD Lathia","year":"2017","unstructured":"Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol. 2017;12:387\u201399.","journal-title":"Target Oncol"},{"key":"7387_CR49","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/0008-5472.CAN-17-1201","volume":"78","author":"EC Saputra","year":"2018","unstructured":"Saputra EC, Huang L, Chen Y, Tucker-Kellogg L. Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer. Cancer Res. 2018;78:2419\u201331.","journal-title":"Cancer Res"},{"key":"7387_CR50","first-page":"241","volume":"2","author":"L Zhao","year":"2010","unstructured":"Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed). 2010;2:241\u20139.","journal-title":"Front Biosci (Elite Ed)"},{"key":"7387_CR51","doi-asserted-by":"crossref","unstructured":"Nami B, Wang Z. HER2 in breast cancer stemness: a negative feedback loop towards trastuzumab resistance. Cancers. 2017;9.","DOI":"10.3390\/cancers9050040"},{"key":"7387_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-020-00242-3","volume":"5","author":"S Zhang","year":"2020","unstructured":"Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther. 2020;5:135.","journal-title":"Signal Transduct Target Ther"},{"key":"7387_CR53","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1158\/0008-5472.CAN-05-0626","volume":"65","author":"D Ponti","year":"2005","unstructured":"Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem\/progenitor cell properties. Cancer Res. 2005;65:5506\u201311.","journal-title":"Cancer Res"},{"key":"7387_CR54","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/s41418-018-0079-6","volume":"25","author":"Y Cho","year":"2018","unstructured":"Cho Y, Kang HG, Kim SJ, Lee S, Jee S, Ahn SG, et al. Post-translational modification of OCT4 in breast cancer tumorigenesis. Cell Death Differ. 2018;25:1781\u201395.","journal-title":"Cell Death Differ"},{"key":"7387_CR55","doi-asserted-by":"crossref","unstructured":"Xu J, Li L, Shi P, Cui H, Yang L. The crucial roles of Bmi-1 in cancer: implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23158231"},{"key":"7387_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-019-05445-z","volume":"179","author":"JP Leone","year":"2020","unstructured":"Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, et al. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020;179:113\u201323.","journal-title":"Breast Cancer Res Treat"},{"key":"7387_CR57","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1634\/theoncologist.2020-0127","volume":"25","author":"J Xu","year":"2020","unstructured":"Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, et al. A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases. Oncologist. 2020;25:652\u201360.","journal-title":"Oncologist"},{"key":"7387_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1144-1","volume":"35","author":"MH Townsend","year":"2018","unstructured":"Townsend MH, Robison RA, O\u2019Neill KL. A review of HPRT and its emerging role in cancer. Med Oncol. 2018;35:89.","journal-title":"Med Oncol"},{"key":"7387_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45.","journal-title":"Mol Cancer"},{"key":"7387_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01503-1","volume":"21","author":"S Raj","year":"2022","unstructured":"Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, et al. Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer. Mol Cancer. 2022;21:31.","journal-title":"Mol Cancer"},{"key":"7387_CR61","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1172\/JCI3304","volume":"103","author":"D Taupin","year":"1999","unstructured":"Taupin D, Wu DC, Jeon WK, Devaney K, Wang TC, Podolsky DK. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Investig. 1999;103:R31\u20138.","journal-title":"J Clin Investig"},{"key":"7387_CR62","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1007\/s00018-005-5481-9","volume":"62","author":"W Hoffmann","year":"2005","unstructured":"Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell Mol Life Sci. 2005;62:2932\u20138.","journal-title":"Cell Mol Life Sci"},{"key":"7387_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsbmb.2015.05.005","volume":"153","author":"VS Wu","year":"2015","unstructured":"Wu VS, Kanaya N, Lo C, Mortimer J, Chen S. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer? J Steroid Biochem Mol Biol. 2015;153:45\u201353.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"7387_CR64","doi-asserted-by":"crossref","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:1\u201331.","DOI":"10.1038\/s41572-019-0111-2"},{"key":"7387_CR65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2012.03.002","volume":"22","author":"K Sampieri","year":"2012","unstructured":"Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol. 2012;22:187\u201393.","journal-title":"Semin Cancer Biol"},{"key":"7387_CR66","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci. 2003;100:3983\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"7387_CR67","doi-asserted-by":"crossref","unstructured":"Zhang X, Powell K, Li L. Breast cancer stem cells: biomarkers, identification and isolation methods, regulating mechanisms, cellular origin, and beyond. Cancers. 2020;12.","DOI":"10.3390\/cancers12123765"},{"key":"7387_CR68","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00018-016-2334-7","volume":"74","author":"F Yang","year":"2017","unstructured":"Yang F, Xu J, Tang L, Guan X. Breast cancer stem cell: the roles and therapeutic implications. Cell Mol Life Sci. 2017;74:951\u201366.","journal-title":"Cell Mol Life Sci"},{"key":"7387_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01768-y","volume":"26","author":"J Park","year":"2024","unstructured":"Park J, Chang ES, Kim J-Y, Chelakkot C, Sung M, Song J-Y, et al. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive\/HER2-negative metastatic breast cancer. Breast Cancer Res. 2024;26:13.","journal-title":"Breast Cancer Res"},{"key":"7387_CR70","doi-asserted-by":"publisher","first-page":"628","DOI":"10.18632\/genesandcancer.148","volume":"8","author":"Y Nozaki","year":"2017","unstructured":"Nozaki Y, Tamori S, Inada M, Katayama R, Nakane H, Minamishima O, et al. Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1-positive breast cancer stem cells and predicts poor clinical outcome in breast cancer. Genes Cancer. 2017;8:628\u201339.","journal-title":"Genes Cancer"},{"key":"7387_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216780","volume":"588","author":"P Jabbarzadeh Kaboli","year":"2024","unstructured":"Jabbarzadeh Kaboli P, Chen H-F, Babaeizad A, Roustai Geraylow K, Yamaguchi H, Hung M-C. Unlocking c-MET: a comprehensive journey into targeted therapies for breast cancer. Cancer Lett. 2024;588:216780.","journal-title":"Cancer Lett"},{"key":"7387_CR72","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1126\/science.1125951","volume":"312","author":"J Baselga","year":"2006","unstructured":"Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006;312:1175\u20138.","journal-title":"Science"},{"key":"7387_CR73","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865\u201378.","journal-title":"Nat Rev Cancer"},{"key":"7387_CR74","doi-asserted-by":"crossref","unstructured":"Gautam SK, Kanchan RK, Siddiqui JA, Maurya SK, Rauth S, Perumal N, et al. Blocking c-MET\/ERBB1 axis prevents brain metastasis in ERBB2+ breast cancer. Cancers. 2020;12:2838.","DOI":"10.3390\/cancers12102838"},{"key":"7387_CR75","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1677\/erc.1.01270","volume":"13","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, et al. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr-Relat Cancer. 2006;13:1085\u201399.","journal-title":"Endocr-Relat Cancer"},{"key":"7387_CR76","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","volume":"68","author":"DL Shattuck","year":"2008","unstructured":"Shattuck DL, Miller JK, Carraway KL 3rd, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008;68:1471\u20137.","journal-title":"Cancer Res"},{"key":"7387_CR77","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/apm.13031","volume":"128","author":"S Mitra","year":"2020","unstructured":"Mitra S, Bal A, Kashyap D, Kumar S, Shrivastav S, Das A, et al. Tumour angiogenesis and c-Met pathway activation\u2014implications in breast cancer. Acta Pathol Microbiol Immunol Scand. 2020;128:316\u201325.","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"7387_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15318-5","volume":"11","author":"LR Kong","year":"2020","unstructured":"Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, et al. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nat Commun. 2020;11:1556.","journal-title":"Nat Commun"},{"key":"7387_CR79","doi-asserted-by":"crossref","unstructured":"Yang L, Li Y, Bhattacharya A, Zhang Y. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Sci Transl Med. 2019;11:eaav1620.","DOI":"10.1126\/scitranslmed.aav1620"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07387-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:15:09Z","timestamp":1738887309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7387"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07387-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4982898\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: PEL has previously consulted for Perseis Therapeutics Ltd. PEL are named on PCT application numbers WO 2006\/69253 and WO 2008\/042435 and US provisional application number 61\/059558 and derivatives thereof. VP, BB, and PEL are named as inventors on PCT application WO\/2018\/226155 (PCT\/SG2018\/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof including US Patent 11,141,402). PEL is an equity holder in Sinotar Pharmaceuticals Ltd which currently holds PCT\/SG2018\/050277 and derivatives thereof including issued US Patent no. 11,141,402. All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal care and experimental protocols for in vivo studies were approved by the Laboratory Animal Ethics Committee (Certificate number: YW) at Peking University Shenzhen, and ethical approval was obtained from Tsinghua Shenzhen International Graduate School (Number: 9, Year 2020). No human research participants were involved in the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"76"}}